Issues
-
Cover Image
Cover Image
Environmental enrichment (EE) is a housing paradigm wherein laboratory animals encounter varied physical, social, and cognitive stimuli—toys, running wheels, and increased bedding—within a larger-than-standard housing space (pictured on cover). EE is a prime model to understand environmental influences on aging dynamics, as it confers an anti-obesity and anti-cancer phenotype that has been implicated in healthy aging and health span extension. In the study starting on page 1075, Queen and colleagues applied EE to young and middle-aged female mice to determine whether the housing paradigm would be able to mitigate age-related deficiencies in metabolic function and thus alter Lewis lung carcinoma (LLC) growth. Concomitant with improved metabolic function in the aged-EE mouse cohort, subcutaneously-implanted LLC tumor growth was inhibited and tumors exhibited alterations in various markers of apoptosis, proliferation, angiogenesis, inflammation, and malignancy. These results validate EE as an anti-cancer model in aged mice and underscore the importance of understanding environmental influences on cancer development in aged populations. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Highlights from the Literature
Commentaries
Review
High-burden Cancers in Middle-income Countries: A Review of Prevention and Early Detection Strategies Targeting At-risk Populations
Research Articles
Transcriptome-wide In Vitro Effects of Aspirin on Patient-derived Normal Colon Organoids
Numerous studies have highlighted a role for aspirin in colorectal cancer chemoprevention, though the mechanisms driving this association remain unclear. We addressed this by showing that aspirin treatment of normal colon organoids diminished the transitamplifying cell population, inhibited prostaglandin synthesis, and dysregulated expression of novel genes implicated in colon tumorigenesis.
The Relationship Between Breast Density Change During Menopause and the Risk of Breast Cancer in Korean Women
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.